Soligenix (SNGX) Stock Price, News & Analysis

Company Overview

Soligenix, Inc. is a biopharmaceutical company focused on developing treatments for rare diseases and medical conditions with limited therapeutic options. The company’s programs target dermatologic, gastrointestinal, inflammatory and infectious diseases, with an emphasis on products that may address significant unmet medical needs.

Soligenix’s development portfolio has included HyBryte (synthetic hypericin), a photodynamic therapy candidate for cutaneous T-cell lymphoma, as well as dusquet, an innate defense regulator peptide being evaluated for inflammatory conditions such as oral mucositis and Behçet’s disease. The company has also developed specialized platforms designed to improve the stability of vaccines and other biologic products, including its ThermoVax technology.

Historically, Soligenix has pursued both biotherapeutic and biodefense programs, including candidates for gastrointestinal graft-versus-host disease and medical countermeasures for potential public-health threats. The company is headquartered in Princeton, New Jersey, and is led by President and Chief Executive Officer Christopher J. Schaber.

Key Stats

• Today's Range: $0.35 to $0.36
• 50-Day Range: $0.35 to $0.41
• 52-Week Range: $0.28 to $1.97
• Volume: 120,152 shs
• Average Volume: 2.59 million shs
• Market Capitalization: $5.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Soligenix Stock Analysis - MarketRank™

Soligenix scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Soligenix has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Soligenix has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Soligenix are expected to grow in the coming year, from ($0.55) to ($0.40) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Soligenix is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Soligenix is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Soligenix has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.39% of the float of Soligenix has been sold short.

Short Interest Ratio / Days to Cover

Soligenix has a short interest ratio ("days to cover") of 1.58, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Soligenix has recently decreased by 3.79%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Soligenix does not currently pay a dividend.

Dividend Growth

Soligenix does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Soligenix this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Soligenix insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.91% of the stock of Soligenix is held by insiders.

Percentage Held by Institutions

3.60% of the stock of Soligenix is held by institutions.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 10/08/2026
• Next Earnings (Estimated): 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SNGX
• CIK: 812796
• Web: www.soligenix.com
• Phone: (609) 538-8200
• Fax: 609-452-6467
• Employees: 14
• Year Founded: 1987

Profitability

• EPS (Trailing Twelve Months): ($0.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.08 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -180.25%
• Return on Assets: -107.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.77
• Quick Ratio: 2.77

Sales & Book Value

• Annual Sales: $120 thousand
• Price / Sales: 42.81
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.52 per share
• Price / Book: 0.67

Miscellaneous

• Outstanding Shares: 14,820,000
• Free Float: 14,541,000
• Market Cap: $5.14 million
• Optionable: Not Optionable
• Beta: 1.99